TriLink BioTechnologies ® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap ® mRNA Capping Technology
TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries. This agreement with Lonza strengthens TriLink’s objective to drive greater access to CleanCap® mRNA capping technologies as the demand for mRNA – a promising therapeutic modality – continues to grow.
According to the terms of the agreement, TriLink® will supply its patented CleanCap® M6, CleanCap® AG 3’OMe, CleanCap® AG, and CleanCap® AU cap analogs for use in Lonza’s global mRNA development and manufacturing services, from pre-clinical through Phase III programs. CleanCap® technology is a one-pot solution with over 95% capping efficiency that streamlines mRNA production processes when compared to legacy capping methods.
“CleanCap® technology is accelerating programs from discovery to the clinic via improved mRNA function, streamlined manufacturing, and maximized capped material yield,” shared Drew Burch, President of Nucleic Acid Production at TriLink. “We’re thrilled to offer our innovative capping solutions to Lonza and its customers.”
Since its launch in 2017, TriLink’s CleanCap® capping technology has continued to advance the mRNA capping industry and is used in a majority of approved mRNA and saRNA vaccines. In May 2023, TriLink introduced its most robust CleanCap analog to date, CleanCap® M6, with studies indicating increased mRNA expression by more than 30% versus enzymatic capping methods.
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.
For more information, visit trilinkbiotech.com.
About Maravai LifeSciences
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
For more information about Maravai LifeSciences, visit maravai.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430716807/en/
Contact information
Liz Robinson of CG Life
TriLink BioTechnologies
lrobinson@cglife.com
312-997-2436
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enercap Holdings and Apex Investments in Joint Venture to Build the World’s Largest Supercap Energy Storage Capacity to Meet Exploding Demand16.9.2024 14:11:00 CEST | Press release
Dubai-based supercap energy storage manufacturer Enercap Holdings and Abu Dhabi-based Apex Investments PSC have formed a joint venture to build 16GWh per year manufacturing capacity of supercap energy storage, a cutting-edge technology with features that surpass the current lithium-ion technology we commonly see. The joint venture is set to meet exponential growth in demand. This will currently be the largest supercap energy storage manufacturing capacity in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240916055477/en/ From left to right - Waseem Ashraf Qureshi, CEO-CTO Enercap, H.E. Khalifah Khoury Chairman Apex Investment and Enercap Energy Holdings, and Mark Blackwell CEO Apex Investments (Photo: AETOSWire) As part of this collaboration, Enercap Energy Holding Limited, the joint venture, will establish a fully automated 10 GWh/year manufacturing facility in Abu Dhabi. Additionally, Enercap Energy Holding Limi
25 Disruptive Technology Startups Join Morgan Stanley Inclusive Ventures Lab’s 10th Cohort16.9.2024 14:00:00 CEST | Press release
Morgan Stanley (NYSE: MS) today announced the 2024 global cohort of the Inclusive Ventures Lab, with 25 companies selected from the Americas and Europe, the Middle East and Africa (EMEA). Over the next five months, the companies will participate in an in-house accelerator program designed to further develop and scale technology and technology-enabled startups in the seed to Series A funding round stage. Chosen from thousands of applications, the 25 startups represent a range of disruptive technologies across industries such as Climate Tech, Retail, Healthcare, FinTech, SaaS, Enterprise Software, Consumer and Travel – with many incorporating AI and sustainability into their products and services. Cohort companies will receive a $250,000 investment (£250,000 in EMEA) from Morgan Stanley, as well as a variety of mentorship opportunities, a tailored entrepreneurship curriculum and business-growth resources from the firm’s ecosystem of internal and external partners. “In today’s challenging
EIG’s MidOcean Energy to Acquire Additional 15% Interest in Peru LNG from Hunt Oil Company16.9.2024 14:00:00 CEST | Press release
MidOcean Energy (“MidOcean” or the “Company”), a liquefied natural gas (LNG) company formed and managed by EIG, a leading institutional investor in the global energy and infrastructure sectors, and Hunt Oil Company (“Hunt”) announced today that they have entered into a definitive agreement whereby MidOcean will acquire an additional 15% interest in Peru LNG (“PLNG”) from Hunt. Following the closing of the transaction, MidOcean’s interest in PLNG will increase from 20% to 35%. Aramco played a pivotal role in the transaction, including undertaking key technical and commercial due diligence as well as engaging with key stakeholders for transaction approval. The transaction will be funded entirely by Aramco, which will increase its interest in MidOcean to 49%. Aramco’s further investment in MidOcean strengthens MidOcean and Aramco’s position in the global LNG market and will provide both parties with further exposure to the only LNG export project in South America. Aramco’s indirect stake
Debiopharm & WhiteLab Genomics Announce a Strategic Partnership to Advance Drug Target and Design in Oncology16.9.2024 14:00:00 CEST | Press release
Debiopharm, a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced the signing of a partnership with WhiteLab Genomics (WLG), a Paris and Boston-based biotech company specializing in Artificial Intelligence for Genomic Medicine R&D. This collaboration aims to achieve two key objectives. The first is to identify cancer-specific receptors that are overexpressed on the surface of cancer cells. The second is to find lead candidates capable of binding to these receptors. Once identified, these agents will be attached to the surface of lipid nanoparticles (LNPs) to enhance active tissue targeting Lipid nanoparticles (LNPs) have emerged as a gold standard vector for drug delivery with the potential to transform the oncology landscape, particularly the genomic medicine field, through their high delivery efficacy. One of the challenges with LNPs is their tendency to accumulate in non-targe
FPT Featured in Discovery Channel Documentary Spotlighting Vietnam’s Tech Revolution16.9.2024 13:16:00 CEST | Press release
“Silicon Delta - The Story of Vietnam’s Tech Revolution,” the latest documentary on Vietnam and its leading tech corporation, FPT, has premiered on Discovery Channel and is available in 10 languages, including English, Japanese, German, Chinese, Korean, and so on. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240915240896/en/ (Graphic: Business Wire) The half-hour documentary traces Vietnam’s emergence to become Southeast Asia's fastest-growing digital economy. It offers a chronological view of Vietnam's evolution, current achievements, and positive future outlook, with the potential to become a global workforce powerhouse. Homegrown, FPT is listed among Asia’s Top 50 IT Services Companies, and the company’s journey into the global arena to a multibillion-dollar corporation today mirrors Vietnam's technological and socioeconomic developments. The documentary showcases FPT’s international expansion from its early days to est
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom